University Medical Center Groningen | Dermatology Department
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior to placebo in reducing NT-proBNP at Week 16.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
342 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Toll Free Number
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal